Topical Ketamine in the Treatment of Complex Regional Pain Syndrome
Author(s): Durham Melissa J, Mekhjian Hovik S, Goad Jeffery A, Lou Mimi, Ding Michelle, Richeimer Steven H
Issue: Mar/Apr 2018 - Volume 22, Number 2
View All Articles in Issue
Page(s): 172-175
Download in electronic PDF format for $75
Abstract: The purpose of this study was to evaluate the effectiveness and adverse effects of topical ketamine in the treatment of complex regional pain syndrome. Retrospective charts were reviewed of patients 18 years or older diagnosed with complex regional pain syndrome and treated with topical ketamine during the study period of May 2006 to April 2013 in an academic medical center specialty pain clinic. Exclusion criteria consisted of subjects who 1) were treated with topical ketamine for pain syndromes other than complex regional pain syndrome, 2) initiated other pain therapies concurrently with topical ketamine, 3) had less than two documented visits, 4) began use of topical ketamine prior to the start of the study period, 5) were under 18 years of age. Subjects with ICD-9 diagnoses codes complex regional pain syndrome-1 or complex regional pain syndrome-2 were identified from encounter-based data and billing records. Data collected for each subject included demographics, description of complex regional pain syndrome, concurrent medications and medical conditions, type of ketamine compound prescribed, duration of therapy, side effects, reasons for discontinuation (if any), and pain scores (numerical pain rating scale; 0 to 10). Data were analyzed using descriptive statistics. Institutional Review Board approval was obtained prior to initiating the study. Sixteen subjects met the inclusion/exclusion criteria for the study, 69% of which were female with an average age of 46 years (range: 24 to 60). Subjects took an average of 3.7 other pain medications (range: 2 to 8), had an average of 2.7 other co-morbid pain conditions (range: 1 to 5), and 1.6 other co-morbid non-pain conditions (range: 0 to 4). Eight (50%) reported that their pain had improved, while 7 (44%) reported a worsening of pain. One reported no change in pain score. No subjects reported adverse effects. Based on the findings in this study, the use of topical ketamine in the treatment of complex regional pain syndrome shows promise due to the overall limited options available to treat this condition, as well as the favorable safety profile of topical agents. Future prospective controlled studies are needed to demonstrate a clear benefit.
Related Keywords:
ketamine, complex regional pain syndrome, topical preparations, CRPS, reflex sympathetic dystrophy syndrome, RSDS, nerve injury, pain relief, analgesia, analgesic, NMDA antagonist, glutamate, drug safety, pain intensity scores, formulations
Related Categories:
PAIN MANAGEMENT, PEER-REVIEWED, ADVERSE DRUG EVENTS, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Topical Ketamine in the Treatment of Complex Regional Pain Syndrome
Durham Melissa J, Mekhjian Hovik S, Goad Jeffery A, Lou Mimi, Ding Michelle, Richeimer Steven H
|
Mar/Apr 2018
Pg. 172-175
|
Oral Methadone for Management of Regional Sympathetic Dystrophy Syndrome: A Case Revisited
Vail Jane
|
May/Jun 2007
Pg. 187-192
|
Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients
Sturn Kayla M, Collin Michael
|
May/Jun 2016
Pg. 197-201
|
Using Compounded Medications for the Topical Treatment of Complex Regional Pain Syndrome Type I Following Trauma: A Case Report
Zur Eyal
|
Jan/Feb 2014
Pg. 14-19
|
Topical Ketamine: A Review of the History, Mechanisms, Uses, Safety, and Future
Rabi Joseph
|
Mar/Apr 2016
Pg. 107-113
|
Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Brown Scott, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
|
May/Jun 2010
Pg. 182-192
|
Topical Ketamine 10% for Neuropathic Pain in Spinal Cord Injury Patients: An Open-Label Trial
Rabi Joseph, Minori Joshua, Abad Hasan, Lee Ray, Gittler Michelle
|
Nov/Dec 2016
Pg. 517-520
|
Burning Mouth Syndrome: A Discussion of a Complex Pathology
Zur Eyal
|
May/Jun 2012
Pg. 196-205
|
Topical Medications for Orofacial Neuropathic Pain
Bramwell Bethany L
|
May/Jun 2010
Pg. 200-203
|
Compounded Pain Formulations: What is the Evidence?
Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
|
Jul/Aug 2014
Pg. 278-286
|
Compounded Pain Formulations: What is the Evidence?
Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
|
Mar/Apr 2024
Pg. 100-109
|
Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
|
Mar/Apr 2024
Pg. 111-116
|
Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
|
Jul/Aug 2015
Pg. 295-300
|
Ketamine for Pain in Hospice Patients
Wood Robert M
|
Jul/Aug 2000
Pg. 253-254
|
Case Study: Personalized Oral Low-dose Naltrexone Titration for Pain Management
Rodriguez Franklin, Carvalho Maria, Banov Fabiana
|
Nov/Dec 2023
Pg. 468-473
|
Equine Cushing’s Syndrome
Vail Jane
|
Jan/Feb 2003
Pg. 27-29
|
Topical Pain Relief: Assessment of Patient Satisfaction with a Novel Compound Containing at Least Ketoprofen
Zugerman Jessie Jean M, Reed Thomas C
|
Nov/Dec 2007
Pg. 514-519
|
PostScription: Treatment of Chronic Pain with Methadone or Levorphanol
McNulty Jack P
|
Mar/Apr 2006
Pg. 159-160
|
A Brief Survey on Prescriber Beliefs Regarding Compounded Topical Pain Medications
Warner Meredith, Tuder Dmitry
|
May/Jun 2014
Pg. 182-188
|
Levorphanol for the Treatment of Severe Chronic Pain
McNulty Jack P
|
May/Jun 2007
Pg. 202-211
|
Return to Top |